Skip to main content

Advertisement

SpringerLink
Log in

The clinical and prognostic significance of paraoxonase-2 in gastric cancer patients: immunohistochemical analysis

  • Research Article
  • Published:
Human Cell Aims and scope Submit manuscript

Abstract

Paraoxonase-2 (PON2) belongs to the paraoxonase (PON) protein family. Unlike paraoxonase-1 (PON1), the expression and significance of PON2 remained largely unknown in gastric cancer (GC). Thus, the purpose of our study was to investigate the role of PON2 in GC. First, we found PON2 expression was obviously increased in GC samples compared with paired normal tissue samples at The Cancer Genome Atlas (TCGA) database. Then the high expression status of PON2 mRNA and protein in GC tissues was confirmed by RT-qPCR and immunohistochemistry. Furthermore, we performed the immunohistochemical analysis to study the correlation between PON2 expression and clinicopathological parameters of GC patients, and found high PON2 expression had significantly positive association with diffuse type, clinical stage, tumor invasion, lymph node metastasis and distant metastasis in GC patients. Moreover, survival analysis suggested GC patients with high PON2 expression resulted in a remarkably shorter overall survival compared with GC patients with low PON2 expression, and high expression of PON2 acted as an unfavorable predictor for overall survival. The in vitro studies indicated that silencing of PON2 expression inhibited GC cell proliferation, migration and invasion. In conclusion, our findings give first evidence that PON2 serves as oncogene in GC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.

    Article  Google Scholar 

  2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

    Article  Google Scholar 

  3. Chen W, Sun K, Zheng R, Zeng H, Zhang S, Xia C, et al. Cancer incidence and mortality in China, 2014. Chin J Cancer Res. 2018;30(1):1–12.

    Article  Google Scholar 

  4. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23(5):700–13.

    Article  Google Scholar 

  5. Moya C, Manez S. Paraoxonases: metabolic role and pharmacological projection. Naunyn Schmiedebergs Arch Pharmacol. 2018;391(4):349–59.

    Article  CAS  Google Scholar 

  6. Furlong CE, Marsillach J, Jarvik GP, Costa LG. Paraoxonases-1, -2 and -3: what are their functions? Chem Biol Interact. 2016;259(Pt B):51–62.

    Article  CAS  Google Scholar 

  7. Devarajan A, Shih D, Reddy ST. Inflammation, infection, cancer and all that..the role of paraoxonases. Adv Exp Med Biol. 2014;824:33–41.

    Article  CAS  Google Scholar 

  8. Geng R, Chen Z, Zhao X, Qiu L, Liu X, Liu R, et al. Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy. PLoS ONE. 2014;9(12):e116027.

    Article  Google Scholar 

  9. Atay AE, Kaplan MA, Evliyaoglu O, Ekin N, Isikdogan A. The predictive role of Paraoxonase 1 (PON1) activity on survival in patients with metastatic and nonmetastatic gastric cancer. Clin Ter. 2014;165(1):e1–5.

    CAS  PubMed  Google Scholar 

  10. Krzystek-Korpacka M, Boehm D, Matusiewicz M, Diakowska D, Grabowski K, Gamian A. Paraoxonase 1 (PON1) status in gastroesophageal malignancies and associated paraneoplastic syndromes—connection with inflammation. Clin Biochem. 2008;41(10–11):804–11.

    Article  CAS  Google Scholar 

  11. Bacchetti T, Ferretti G, Sahebkar A. The role of paraoxonase in cancer. Semin Cancer Biol. 2017.

  12. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem. 2001;276(48):44444–9.

    Article  CAS  Google Scholar 

  13. Devarajan A, Bourquard N, Hama S, Navab M, Grijalva VR, Morvardi S, et al. Paraoxonase 2 deficiency alters mitochondrial function and exacerbates the development of atherosclerosis. Antioxid Redox Signal. 2011;14(3):341–51.

    Article  CAS  Google Scholar 

  14. Altenhofer S, Witte I, Teiber JF, Wilgenbus P, Pautz A, Li H, et al. One enzyme, two functions: PON2 prevents mitochondrial superoxide formation and apoptosis independent from its lactonase activity. J Biol Chem. 2010;285(32):24398–403.

    Article  Google Scholar 

  15. Witte I, Foerstermann U, Devarajan A, Reddy ST, Horke S. Protectors or traitors: the roles of PON2 and PON3 in atherosclerosis and cancer. J Lipids. 2012;2012:342806.

    Article  Google Scholar 

  16. Ribarska T, Ingenwerth M, Goering W, Engers R, Schulz WA. Epigenetic inactivation of the placentally imprinted tumor suppressor gene TFPI2 in prostate carcinoma. Cancer Genom Proteom. 2010;7(2):51–60.

    CAS  Google Scholar 

  17. Bacchetti T, Sartini D, Pozzi V, Cacciamani T, Ferretti G, Emanuelli M. Exploring the role of paraoxonase-2 in bladder cancer: analyses performed on tissue samples, urines and cell cultures. Oncotarget. 2017;8(17):28785–95.

    Article  Google Scholar 

  18. Devarajan A, Su F, Grijalva V, Yalamanchi M, Yalamanchi A, Gao F, et al. Paraoxonase 2 overexpression inhibits tumor development in a mouse model of ovarian cancer. Cell Death Dis. 2018;9(3):392.

    Article  Google Scholar 

  19. Wang R, Li J, Zhao Y, Li Y, Yin L. Investigating the therapeutic potential and mechanism of curcumin in breast cancer based on RNA sequencing and bioinformatics analysis. Breast Cancer. 2018;25(2):206–12.

    Article  Google Scholar 

  20. Nagarajan A, Dogra SK, Sun L, Gandotra N, Ho T, Cai G, et al. Paraoxonase 2 facilitates pancreatic cancer growth and metastasis by stimulating GLUT1-mediated glucose transport. Mol Cell. 2017;67(4):685–701.

    Article  CAS  Google Scholar 

  21. Kruger M, Pabst AM, Al-Nawas B, Horke S, Moergel M. Paraoxonase-2 (PON2) protects oral squamous cell cancer cells against irradiation-induced apoptosis. J Cancer Res Clin Oncol. 2015;141(10):1757–66.

    Article  Google Scholar 

  22. Tseng JH, Chen CY, Chen PC, Hsiao SH, Fan CC, Liang YC, et al. Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression. Oncotarget. 2017;8(9):14666–79.

    Article  Google Scholar 

  23. Witte I, Altenhofer S, Wilgenbus P, Amort J, Clement AM, Pautz A, et al. Beyond reduction of atherosclerosis: PON2 provides apoptosis resistance and stabilizes tumor cells. Cell Death Dis. 2011;2:e112.

    Article  CAS  Google Scholar 

  24. Kruger M, Amort J, Wilgenbus P, Helmstadter JP, Grechowa I, Ebert J, et al. The anti-apoptotic PON2 protein is Wnt/beta-catenin-regulated and correlates with radiotherapy resistance in OSCC patients. Oncotarget. 2016;7(32):51082–95.

    Article  Google Scholar 

  25. Kang H, Chen IM, Wilson CS, Bedrick EJ, Harvey RC, Atlas SR, et al. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood. 2010;115(7):1394–405.

    Article  CAS  Google Scholar 

  26. Shakhparonov MI, Antipova NV, Shender VO, Shnaider PV, Arapidi GP, Pestov NB, et al. Expression and intracellular localization of paraoxonase 2 in different types of malignancies. Acta Naturae. 2018;10(3):92–9.

    Article  CAS  Google Scholar 

  27. Frank O, Brors B, Fabarius A, Li L, Haak M, Merk S, et al. Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. Leukemia. 2006;20(8):1400–7.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was funded by Jiangsu Institute of Cancer Research Fund (No. ZM201707) and Jiangsu Youth Fund (No. BK20181091). We thank Mr. Zhang Jingyuan and Chen Yan for their preciseness laboratory technical expertise.

Author information

Author notes

  1. Xiaohua Wang, Guifang Xu and Jingyuan Zhang are co-first authors.

Authors and Affiliations

  1. Department of Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 210009, Jiangsu, China

    Xiaohua Wang, Guoren Zhou & Jianwei Lu

  2. Department of Gastroenterology, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu, China

    Guifang Xu

  3. Department of Pathology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 210009, Jiangsu, China

    Jingyuan Zhang

  4. Department of Pharmacy, China Pharmaceutical University, Nanjing, 210029, Jiangsu, China

    Shuaiyu Wang

  5. Department of Clinical Medicine, Nanjing Medical University, Nanjing, 210029, Jiangsu, China

    Min Ji, Lei Mo, Mengxia Zhu & Jun Li

  6. Department of Radiotherapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, No. 42 Baiziting Road, Nanjing, 210009, Jiangsu, China

    Cheng Chen

Authors
  1. Xiaohua Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guifang Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jingyuan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shuaiyu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Min Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lei Mo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mengxia Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jun Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Guoren Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jianwei Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Cheng Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Guoren Zhou, Jianwei Lu, and Cheng Chen: designed the experiment, interpreted the data, and prepared the manuscript. Xiaohua Wang, Guifang Xu, Jingyuan Zhang, Shuaiyu Wang, Min Ji, Lei Mo, Mengxia Zhu, and Jun Li: conducted the experiment, collected the data, and reviewed the manuscript.

Corresponding authors

Correspondence to Guoren Zhou, Jianwei Lu or Cheng Chen.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, X., Xu, G., Zhang, J. et al. The clinical and prognostic significance of paraoxonase-2 in gastric cancer patients: immunohistochemical analysis. Human Cell 32, 487–494 (2019). https://doi.org/10.1007/s13577-019-00263-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13577-019-00263-3

Keywords

Search

Navigation